SGN-CD19B, a Pyrrolobenzodiazepine (PBD)-Based Anti-CD19 Drug Conjugate, Demonstrates Potent Preclinical Activity Against B-Cell Malignancies

被引：3
|
作者：
Ryan, Maureen C. [1 ]
Schimpf, Brian [1 ]
Anderson, Martha [1 ]
Zeng, Weiping [1 ]
Emmerton, Kim [1 ]
Miyamoto, Jamie [1 ]
Kostner, Heather [1 ]
Yu, Changpu [1 ]
Van Epps, Heather [1 ]
Tatalick, Laurie [1 ]
Benjamin, Dennis [1 ]
机构：
[1] Seattle Genet Inc, Translat Res, Bothell, WA USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.594.594
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Sequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma
    Lownik, Joseph
    Boiarsky, Jonathan
    Birhiray, Ruemu
    Merchant, Akil
    Mead, Monica
    CLINICAL CANCER RESEARCH, 2024, 30 (14) : 2895 - 2904
  • [22] Novel Anti-CD19/Idiotype Bispecific Diabody Vaccine for B-Cell Lymphoma
    Ng, Patrick P.
    Jia, Ming
    Virrueta, Alejandro
    Patel, Kedar
    Swartz, James R.
    Levy, Shoshana
    Levy, Ronald
    BLOOD, 2009, 114 (22) : 1062 - 1062
  • [23] Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies
    van der Horst, Hilma J.
    Oostindie, Simone C.
    Cillessen, Saskia. A. G. M.
    Gelderloos, Anne T.
    Overdijk, Marije B.
    Nijhof, Inger. S.
    Zweegman, Sonja
    Chamuleau, Martine E. D.
    Breij, Esther C. W.
    Mutis, Tuna
    HEMASPHERE, 2021, 5 (01):
  • [24] Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma
    Pier Luigi Zinzani
    Giorgio Minotti
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 177 - 190
  • [25] Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma
    Zinzani, Pier Luigi
    Minotti, Giorgio
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) : 177 - 190
  • [26] Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy
    Perez, Arianne
    Navale, Lynn
    Rossi, John M.
    Shen, Yueh-wei
    Jiang, Yizhou
    Sherman, Marika
    Mardiros, Armen
    Yoder, Sean C.
    Go, William Y.
    Rosenberg, Steven A.
    Wiezorek, Jeff
    Roberts, Margo R.
    Chang, David D.
    Kochenderfer, James N.
    Bot, Adrian
    BLOOD, 2015, 126 (23)
  • [27] Treatment of Chemotherapy-Refractory B-Cell Malignancies with Anti-CD19 Chimeric Antigen Receptor T Cells
    Kochenderfer, James N.
    Kassim, Sadik H.
    Somerville, Robert
    Dudley, Mark E.
    Carpenter, Robert O.
    Lu, Lily
    Feldman, Steven A.
    Morton, Kathleen E.
    Toomey, Mary Ann
    Rosenberg, Steven A.
    MOLECULAR THERAPY, 2014, 22 : S295 - S295
  • [28] Anti-CD19-CD22 antibody drug conjugate to reduce tumor recurrence in B-cell hematologic cancers
    Du, Liang
    Wan, Tingting
    Jin, Yi
    Yuan, Jijun
    CANCER RESEARCH, 2022, 82 (12)
  • [29] Non-depleting anti-CD19 B cell inhibition
    Robert Phillips
    Nature Reviews Rheumatology, 2023, 19 : 539 - 539
  • [30] Non-depleting anti-CD19 B cell inhibition
    Phillips, Robert
    NATURE REVIEWS RHEUMATOLOGY, 2023, 19 (09) : 539 - 539
12345